Regeneron is no longer primarily an eye-drug company that happens to own a share of a blockbuster antibody. The second-quarter print shows a profit-share machine, built around Dupixent and the Sanofi antibody collaboration, carrying the equity while the owned retina book keeps shrinking. That is the transition the market has been waiting to see in the numbers, and it is now visible. The Sanofi development balance, a multi-year overhang that reduced reported collaboration profits, is fully repaid as of mid-year. From the third quarter, that drag no longer sits on the collaboration line.
Owned product sales barely moved, at $1642 million, because a 52 percent jump in high-dose aflibercept was offset by a collapse in legacy Eylea. Total United States retina sales still fell. Collaboration revenue from Sanofi jumped to $2174 million as Dupixent global sales, booked by the partner, reached $6 billion. The income statement is therefore telling two stories at once: a partnered immunology engine that is accelerating, and a company-owned franchise that is still in net decline even after a successful high-dose conversion.
Headline revenue rose 17 percent to $4291 million, and adjusted earnings rose even as reported profit fell on a large in-process research charge and a higher tax rate. Libtayo set another sales high, and the company still runs about fifty clinical programs. The question for the next several quarters is whether owned products can start growing again, or whether Regeneron is becoming a Dupixent royalty company that happens to spend heavily on science.